2174 ⎘
Modified animals Animals treated with compounds which are neither proteins nor nucleic acids
Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models
#2ZEBRAFISH ANIMAL MODEL FOR INFLAMMATORY DISEASES AND METHOD FOR SCREEING ANTI-INFLAMMATORY AGENTS USING SAME
#3Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
#4TELOMERASE REVERSE TRANSCRIPTASE THERAPY FOR KIDNEY FIBROSIS AND NON-HUMAN ANIMALS THEREOF
#5BILIARY ATRESIA MODEL
#6TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
#7ESTABLISHMENT AND APPLICATION OF MURINE MODELS OF HYPERURICEMIA-EXACERBATED PERIODONTITIS
#8PROTEINS WITH CARDIOPROTECTIVE ACTIVITY
#9COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING ALZHEIMER'S DISEASE
#10SCREENING METHOD OF PROBIOTIC AND ACTIVE SUBSTANCE FOR PROMOTING REPRODUCTIVE HEALTH AND USE
#11ANTHELMINTIC LABORATORY ANIMAL MODEL FOR HEARTWORM
#12NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF
#13METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL
#14COMPOSITION FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE
#15A NON-HUMAN ANIMAL MAMMALIAN MODEL OF CHRONIC GLAUCOMA
#16NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY
#17SEX DETERMINATION MARKERS IN MULLETS AND METHODS OF USING THEREOF
#18Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF2
#19NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF
#20Proteins with cardioprotective activity
#21ORGAN REGENERATION METHOD UTILIZING BLASTOCYST COMPLEMENTATION
#22METHOD OF PREPARING MOUSE MODEL OF HERPES
#23MOUSE MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
#24GENE THERAPIES FOR LYSOSOMAL DISORDERS
#25PROTEINS WITH CARDIOPROTECTIVE ACTIVITY
#26Compositions for treating pathological calcification conditions, and methods using same
#27Mouse model of alcohol-induced liver cancer
#28ANTHELMINTIC LABORATORY ANIMAL MODEL FOR HEARTWORM
#29Conditioning regimens and methods for inducing mixed chimerism
#30METHOD FOR ESTABLISHING AN ORAL ULCER ANIMAL MODEL WITH YIN-DEFICIENCY AND FIRE-EXCESS SYNDROME BASED ON SLEEP DEPRIVATION
#31GRAVES' OPHTHALMOPATHY PHENOTYPE ANIMAL MODEL, CONSTRUCTION METHOD THEREFOR, AND METHOD FOR SCREENING THERAPEUTIC MATERIAL FOR GRAVES' OPHTHALMOPATHY
#32COMPOSITIONS AND METHODS FOR TREATING REFRACTORY SEIZURES
#33GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS TARGETING GANGLIOSIDE BIOSYNTHETIC PATHWAYS
#34NON-HUMAN ANIMALS EXHIBITING DEGENERATIVE SYMPTOM ATTRIBUTED TO PROTEIN AGGREGATION
#35Non-Human Animal Model of Non-Alcoholic Fatty Liver Disease
#36Method for improving immunity in shrimps
#37Methods for treating pseudoxanthoma elasticum (PXE)
#38INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE
#39Compositions for treating pathological calcification conditions, and methods using same
#40Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity by UPF1
#41INFORMATION PROVIDING METHOD FOR DIAGNOSING PARKINSONS DISEASE
#42Recombinant HIV compositions and uses thereof in animal models
#43Method for Treating Ischemic Tissue
#44ORGAN REGENERATION METHOD UTILIZING BLASTOCYST COMPLEMENTATION
#45A NON-HUMAN ANIMAL MODEL OF NEURODEGENERATIVE DISORDERS
#46INSECT AND CANNABIS PRODUCTION SYSTEMS AND METHODS
#47Compositions for treating pathological calcification conditions, and methods using same
#48Vaccine comprising drug and parasite administration
#49METHODS AND COMPOSITIONS RELATING TO IMPROVED HUMAN RED BLOOD CELL SURVIVAL IN GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMALS
#50Method for producing animal model of preterm birth and animal model of preterm birth produced by the method
#51Anti-obesity microbiota compositions and preparation methods and uses thereof
#52Conditioning regimens and methods for inducing mixed chimerism
#53Methods of agent delivery into eggs and embryos of egg-producing aquatic animals for drug screening, agent toxicity assay and production of infertile fish
#54Preclinical model of neonatal necrotizing enterocolitis
#55Non-human primate model of age-related macular degeneration and method for producing same
#56Method for injectable delivery of a therapeutic agent into a fish embryo
#57Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
#58Reducing the reproductive capacity of mammals
#59METHODS AND MATERIALS FOR USING TRANSGENIC NON-HUMAN ANIMALS EXPRESSING SODIUM IODIDE SYMPORTER POLYPEPTIDES TO MONITOR PATHOLOGICAL PROCESSES, DISEASE PROGRESSION, OR THERAPEUTIC RESPONSES OVER TIME
#60Compositions for treating pathological calcification conditions, and methods using same
#61Compositions for treating pathological calcification conditions, and methods using same
#62Compositions for treating pathological calcification conditions, methods, and host cells using the same
#63ANIMAL MODEL FOR DRY EYE AND METHODS OF USE OF SUCH ANIMALS
#64Compositions for treating pathological calcification conditions, and methods using same
#65Compositions for treating pathological calcification conditions, and methods using same
#66Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290
#67ORGAN REGENERATION METHOD UTILIZING BLASTOCYST COMPLEMENTATION
#68METHOD FOR PRODUCING ANIMAL MODEL OF OSTEOBLASTIC BONE METASTASIS
#69Method for Preventing or Treating a Protein Aggregation Disease
#70NOVEL GERM CELL ABLATION COMPOUNDS AND USES THEREOF
#71Genetically modified non-human animals and methods relating to innate immune system response detection
#72GENETICALLY MODIFIED RAT MODELS FOR PHARMACOKINETICS
#73Compositions, methods, and devices for dialysis
#74Prophylactic and/or therapeutic agent for inflammatory disease, and method for screening prophylactic and/or therapeutic drug for inflammatory disease
#75MODEL OF ALZHEIMER'S DISEASE
#76Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
#77Methods of reducing TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis by a UPF1 polypeptide or polynucleotide
#78Reducing the reproductive capacity of mammals
#79HUMANIZED MOUSE
#80Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
#81Germ cell ablation compounds and uses thereof
#82Steatohepatitis-liver cancer model animal
#83Establishment of rhesus monkey model of autoimmunity type 1 diabetes
#84Model system of keratitis syndrome and method for selecting a treatment thereof
#85METHODS AND SYSTEMS FOR INDUCIBLE ABLATION OF NEURAL CELLS
#86Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
#87THERAPEUTIC USE OF A GROWTH FACTOR, NSG33
#88Compositions And Methods Of Inhibiting NADPH Oxidase Expression
#89STEATOHEPATITIS-LIVER CANCER MODEL ANIMAL
#90Dry eye animal model
#91Mouse having human leukemic stem cell and leukemic non-stem cell amplified therein, and method for production thereof
#92Methods concerning PPAR delta and antagonists thereof
#93Modulation of SMRT expression
#94Genetically Modified Rat Models for Pharmacokinetics
#95ANIMAL MODEL FOR DIABETES
#96Pathological animal model for pelvic pain syndrome
#97COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION
#98Microspheres
#99METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASE
#100Organ regeneration method utilizing blastocyst complementation
#101Chemical inhibitors of inhibitors of differentiation
#102Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions
#103Systemic Treatment of Metastatic and/or Systemically-Disseminated Cancers using GM-CSF-Expressing Poxviruses
#104Therapeutic use of a growth factor, NsG33
#105Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
#106Use of agonists and antagonists of IL-23 in the treatment of viral infection
#107Methods and compositions for the treatment of neurological disease